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Background/aim: Operative bleeding is one of the major determinants of outcome in liver surgery. This study aimed to describe the
impact of intraoperative blood loss on the postoperative course of liver resection (LR).
Materials and methods: The data of 257 patients who were treated with LR between January 2007 and October 2018 were retrospectively
analyzed. LRs were performed via intermittent portal triad clamping (PTC) under low central venous pressure.
Results: LRs were performed for 67.7% of patients with a malignant disease and 32.3% of patients with a benign disease. Major LR was
performed in 89 patients (34.6%). The mean PTC period was 20.32 min (±13.7). The median intraoperative bleeding amount was 200
mL (5–3500 mL), the 30-day mortality rate was 4.3%, and the morbidity rate was 31.9%. The hospital stay (p = 0.002), morbidity (p =
0.009), and 30-day mortality (p = 0.041) of patients with a bleeding amount of more than 500 mL significantly increased.
Conclusion: Surgeons should consider the adverse effects of intraoperative bleeding during liver resection on patients’ outcome.
Favorable outcomes would be obtained with diligent postoperative care.
Key words: Liver surgery, operative bleeding, portal triad clamping, low central venous pressure, hemostasis

1. Introduction
The need of perioperative blood transfusion is reported
between 20% and 50% of major LRs [1–5]. Operative
blood loss and exposure to allogenic blood are associated
with poor outcomes in patients undergoing LR [1–3].
Liver-specific complications seen after LR are biliary
leak, bleeding, and posthepatectomy liver failure (PHLF).
In the early studies, bleeding was the primary cause of
overall mortality following LR. The mortality for hepatic
resections has improved significantly since the 90s and
the bleeding accounts for a minor percentage of overall
morbidity in the current series. However, other outcomes
have not improved in parallel with mortality such that
overall morbidity is still reported in the range of 14% to
45% [4].
Some of the important strategies to control blood
loss during LR are afferent or complete devascularization
before parenchymal transection, low central venous
pressure (CVP) surgery, and temporary occlusion of blood

inflow with or without outflow control [6]. For precise
hemostasis during parenchymal transection, devices such
as ultrasonic dissectors, heat coagulants, or bipolar vessel
sealants are used [7,8].
In this study, we presented the results of our policy on
controlling bleeding and hemostasis during LR. We also
briefly discussed the strategies to minimize blood loss in
liver surgery.
2. Materials and methods
A total of 271 patients underwent LR between January 2007
and November 2018 in Karadeniz Technical University
Hospital. Exclusion criteria were as follows: age of 16 years
or younger, surgery on the liver without parenchymal
resection (including inoperable cases), and LR performed
because of liver trauma (n = 5). The authors analyzed only
the data of the first LR attempts in patients who underwent
liver reresection (n = 16). Overall, 257 patients were
considered eligible for this study. The patients’ data were
prospectively recorded and retrospectively analyzed.
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2.1. Patient selection
The status of the functional liver was evaluated in terms of
Child–Pugh–Turcotte (CPT) scores. Patients with a CPT
score greater than seven and a model for end-stage liver
disease score greater than 16 were considered for the liver
transplantation. Future liver remnants were calculated
with the help of volumetric analyses from CT images.
In the presence of biliary obstruction upon admission,
cholestasis was managed with percutaneous transhepatic
biliary drainage before the operation. The patients were
monitored without operation until the total bilirubin level
decreased to 3 mg/dL.
2.2. Liver resection and perioperative care
CVP was maintained at less than 5 cm H2O during LR.
LRs were performed through a J-shaped right subcostal
incision. A conventional technique including intermittent
PTC in 15/5 min cycles of clamp/unclamp times has
been used for LRs [2,9–11]. The liver was transected via
clamp crushing and a vessel sealing device (LigaSureTM,
Medtronic plc, Minneapolis, MN, USA). Major LR was
defined as the resection of three or more segments. A
variety of LR types are listed according to diagnosis
in Table 1. After macroscopic leakage was initially
controlled, a fibrin sealant (Tisseel, Baxter Healthcare
Corp., Westlake Village, CA, USA) was applied to the
cut surface. The whole part of the cut surface was then
coated with oxidized cellulose (Surgicel Fibrillar, Ethicon
SÀRL, Puits-Godet 20, Neuchâtel, Switzerland). Resection
of common hepatic duct was required in patients with
Klatskin tumor (n = 22/22) and alveolar hydatid disease
(n = 3/16) related to disease invasion or disease extension
(in a patient with hepatholithiasis). Hepaticojejunostomy
was carried out with interrupted 5/0 polydioxanone (PDS)
sutures. The operation field was drained with classic
perforated Jackson Pratt silicone drains (Cardinal Health,
Dublin, OH, USA). The fascial planes of the incision were
closed with a running no. 1 PDS suture [10]. Antibiotic
prophylaxis composed of ceftriaxone (1 × 2 g/day) was
initially given within 1 h before incision and continuously
administered for 5 postoperative days (PODs) to patients
without systemic inflammatory response syndrome. In
the presence of bilioenteric anastomosis, metronidazole
was added to the ceftriaxone treatment. The patients
also received prophylactic daily subcutaneous injection
of low-molecular-weight heparin (LMWH) beginning
POD 0. LMWH treatment was continued until the first
postoperative month was completed.
2.3. Postoperative follow-up and data collection
The patients were provided with standardized pulmonary
care 1 day after extubation [2]. Drains were removed
within 5 PODs in the absence of a suspicious content
of hemorrhage or biliary leak. PHLF was diagnosed in
accordance with the International Study Group of Liver

Surgery (ISGLS) criteria [12]. In the case of PHLF, our
algorithm was applied to support the failing liver [13].
2.4. Statistical analysis
Receiver operating characteristic (ROC) curves were used
to determine the optimal cut point of the total bleeding
volume. The maximum value of Youden index was used to
divide the patients into two groups in terms of operative
bleeding (for 500 mL, sensitivity = 0.284 and specificity =
0.898). Categorical variables were comparatively analyzed
using a chi-square test and Fisher’s exact test. Quantitative
parameters were examined using an independent sample
t-test or the Mann–Whitney U test as appropriate.
Univariate and multivariate analyses were performed using
the Cox proportional hazard regression model. Differences
at p < 0.05 were considered statistically significant.
3. Results
The demographic and operative parameters were
summarized in Table 2. Overall morbidity rate was 31.9%.
Pulmonary complications were the leading causes of
morbidity (n = 70/82). Pneumonia was evolved to sepsis
in four patients. Pulmonary embolism (PE) was the worst
complication (mortality rate of 60%) in the study group.
The incidence of biliary leak was 6.6% (n = 17). The biliary
leak originated from the cut surface of the remnant liver (n
= 11), the bilioenteric anastomosis (n = 5), or the stump of
the right hepatic duct (n = 1). Biliary leak was controlled
with relaparotomy (n = 3) or percutaneous drainage (n =
10). Surgical site infections (SSIs) were observed in 15 cases
(5.8%). Eight patients suffered from superficial SSIs, whereas
four patients had deep SSI. Three patients with organ/space
SSIs had dehiscence. Furthermore, 14 (5.4%) cases had
PHLF that generally developed after major LR (n=11/14)
and resection for malignancy (n=11/14). Six of the 14 cases
with PHLF had chronic liver disease before operation. Five
patients were in stage C, six patients were in stage B, and
three patients were in stage A. With the help of our treatment
policy for PHLF, 11 of the 14 patients survived. Seven
patients were reoperated within the early postoperative
period (30-day after operation) because of biliary leak (n
= 2), biliary obstruction (n = 1), dehiscence secondary to
organ/space SSIs (n = 3), and postoperative bleeding (n
= 1). The multivariate analyses indicated that malignant
etiology and transfusion of erythrocyte suspension were
independent risk factors for the development of morbidity
after liver resection (Table 3).
Overall, the 30-day mortality rate was 4.3%. The patients
died from PE (n = 3), sepsis (n = 4), PHLF (n = 3), and acute
myocardial infarction (MI, n = 1). The progression of PHLF
was not controlled in three patients who died within the first
postoperative week. All the patients who died from PHLF
had chronic liver diseases (Hepatitis B virus infection, n =
2 and Hepatitis C virus infection, n = 1) and two of them
underwent major LR.
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Table 1. Types of liver resection.
Malignant diseases, n (%)
Diagnosis

HCC

Klatskin tumor

IHCC
Gallbladder
carcinoma

Benign diseases, n (%)

Major LR,
62 (35.6)

Minor LR,
112 (64.4)

N = 174

RH

6

Sec.

16

ERH

3

Seg.

29

LH

4

ELH

2

Seg.≥3

3

RH

4

ERH

3

LH

10

ELH

5

RH

2

ELH

1

Seg.≥3

1

69
NASSLR

22

Seg.

2

NASSLR

2

Seg.

7

NASSLR

2

Hepatolithiasis

3

Sec.

14

ERH

2

Seg.

9

ELH

1

Seg.≥3

9

NASSLR

14

Seg.≥3

1

Seg.
NASSLR
Sec+
NASSLR
Seg.

2
1

4

1

1

1

2

Gastric cancer
metastasis

Seg.

1

1

Testis tumor
metastasis

NASSLR

1

1

Bladder carcinoma
metastasis

Seg.

1

1

RCC metastasis

Seg.

1

1

Parotid tumor
metastasis

Seg.

1

1

GIST metastasis

Seg.

1

1

Lymphoma

RH

1

Alveolar
hydatid
disease

8

RH

NET metastasis

Major LR,
27 (32.5)

Minor LR, 56
(67.5)

RH

1

Sec.

9

LH

2

Seg.

23

ELH

1

Seg.≥3

5

NASSLR

3

Sec.

5

Seg.

3

Sec.

2

Seg.

3

Sec.

1

7

NASSLR

5

5

Seg.

2

3

Hydatid cyst
of the liver

1

Breast carcinoma
metastasis

Giant
hemangioma

6

RH

CRC metastasis

Diagnosis

10

RH

3

ERH

1

LH

2

ELH

2

Seg.≥3

3

RH

1

LH

5

Granuloma

N = 83

44

8

16

52

Focal nodular
hyperplasia

RH

1

Abbreviations: LR, liver resection; RH, right hepatectomy; ERH, extended right hepatectomy; LH, left hepatectomy, ELH, extended left
hepatectomy; Seg., segmentectomy; Sec., sectorectomy; NASSLR, nonanatomical subsegmentary liver resection; HCC, hepatocellular
carcinoma; IHCC, intrahepatic cholangiocarcinoma; CRC, colorectal carcinoma; NET, neuroendocrine tumor; RCC, renal cell
carcinoma; GIST, gastrointestinal stromal tumor.

The morbidity rate, hospital stay, and the mortality rate
of the patients with a bleeding amount of more than 500
mL significantly increased compared to that of the patients
with a bleeding amount of less than 500 mL (Table 4).
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4. Discussion
The critical threshold of bleeding amount that causes
morbidity and mortality in liver surgery is unclear. Most
trials have found that the average amount of blood loss
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Table 2. Univariate analysis of risk factors for morbidity and hospital mortality.
Variable

n

Morbidity

p

Mortality

p

Sex
Male
Female
Age (years, mean ± SEM)

149
108
56.33 (±13.61)

51 (34.2%)
31 (28.7%)
59.34 (±12.71)

0.348

0.611

0.015

7 (4.7%)
5 (4.6%)
61 (±10.91)

BMI (kg/m2, Mean ± SEM)
ASA
ASA 1
ASA 2
ASA 3
ASA 4
DM
Yes
No
COPD
Yes
No
CAD
Yes
No
HBV-positive
Yes
No
HCV-positive
Yes
No
Diagnosis
Benign
Malignant
Cirrhotic liver
Yes
No
Extent of resection
Minor
Major
Extrahepatic procedure
Yes
No
Operation time (min, mean ± SEM)

26.41 (±4.41)

26.68 (±4.29)

0.487

25.64 (±3.99)

0.633

80
141
34
2

16 (20%)
51 (36.2%)
13 (38.2%)
2 (100%)

33
224

17 (51.5%)
65 (29%)

0.010

2 (6.1%)
10 (4.5%)

0.656

14
243

5 (35.7%)
77 (31.7%)

0.479

1 (7.1%)
11 (4.5%)

0.497

16
241

5 (31.3%)
77 (32.1%)

0.945

2 (12.5%)
10 (4.2%)

0.167

48
209

14 (29.2%)
68 (32.5%)

0.652

2 (4.2%)
10 (4.8%)

1.000

19
238

10 (52.6%)
72 (30.3%)

0.044

1 (5.3%)
11 (4.6%)

1.000

83
174

15 (18.1%)
44 (38.5%)

0.001

0 (0%)
12 (6.9%)

0.011

57
200

23 (40.4%)
59 (29.5%)

0.121

3 (5.3%)
9 (4.5%)

0.732

168
89

44 (26.2%)
38 (42.7%)

0.004

5 (2.9%)
7 (7.9%)

0.113

57
200
155.74 (±86.62)

25 (43.9%)
57 (25.8%)
184.71 (±105.67)

0.028

0.146

0.014

5 (8.8%)
7 (3.5%)
205.42 (±135.64)

PTC period (min, mean ± SEM)
Blood loss
<500 mL
≥500 mL
ES transfusion
Yes
No
FFP transfusion
Yes
No

20.32 (±13.7)

21.09 (±14.05)

0.400

16.75 (11.78%)

0.567

189
68

53 (28.0%)
29 (42.6%)

0.027

6 (3.2%)
6 (8.8%)

0.088

72
185

37 (51.4%)
45 (24.3%)

<0.001

8 (11.1%)
4 (2.2%)

0.005

189
68

66 (34.9%)
16 (23.5%)

0.084

10 (5.3%)
2 (2.9%)

0.738

0.008

4 (5%)
3 (3.5%)
3 (8.8%)
0 (0%)

0.246

0.403

0.358

Abbreviations: ASA, American Society of Anesthesia; BMI, body mass index; CAD, coronary artery disease; COPD, chronic obstructive
pulmonary disease; DM, diabetes mellitus; ES, erythrocyte suspension; HBV, hepatitis B virus; HCV, hepatitis C virus; PTC, portal triad
clamping; FFP, fresh frozen plasma; SEM, standard error of the mean.
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Table 3. Significant factors for morbidity by mutivariant analysis.
Univariate

Multivariate

Variable

OR (95% CI)

p

Age

1.03 (1.01–1.05)

0.016

ASA
ASA 2
ASA 3–4

2.27 (1.19–4.33)
2.86 (1.21–6.75)

0.021
0.013
0.017

DM

2.60 (1.24–5.45)

0.012

Diagnosis (benign/malignant)

2.84 (1.50-5.39)

0.001

Extent of resection

2.22 (1.29–3.83)

0.004

Extrahepatic procedure

1.96 (1.07–3.60)

0.03

Blood loss

1.91 (1.07–3.39)

0.028

ES transfusion

3.29 (1.86–5.82)

<0.001

FFP transfusion

1.74 (0.92–3.29)

0.086

OR (95% Cl)

p

2.74 (1.43–5.28)

0.003

3.20 (1.78–5.73)

<0.001

The Cox proportional hazard regression model was used. Abbreviations: CI, confidence interval; OR, odds ratio.

in patients who undergo LR to is around 300 mL [14,15].
Our ROC curve analysis revealed that the cutoff point of
operative bleeding was 500 mL. The cutoff point of bleeding
during LR for disease treatment is completely different
from that for donation. Ibrahim claimed that the morbidity
of patients significantly increases with a bleeding amount
of as low as 170 ± 79 mL during donor hepatectomy [16].
However, Yang determined 800 mL as a cutoff point of the
significant bleeding amount that leads to morbidity [17].
The featured points of previous studies were similar major
LR rates, completely normal liver parenchyma in the first
study, and the presence of an underlying liver disease with
HCC in the second one. In another study, the morbidity
rate significantly increases with a bleeding amount of
more than 1000 mL during LR [18]. The patient spectrum
in our study seemed similar, but the major LR rates were
lower than those in a previous study. However, the study
interval between the two series was completely different.
The implementation of technological devices in surgical
techniques has altered the amount of bleeding in liver
surgery, especially in the 2000s compared with the 1990s.
Therefore, the bleeding threshold for the determination
of morbidity in liver surgery should be lower than 1000
mL in current studies. If the cutoff point of the bleeding
amount would be optimized, then 200–800 mL should be
set in liver resection for disease treatment.
Systematic metaanalyses have shown that low-CVP
surgery reduces the amount of blood loss and the need for
transfusion during a LR [14,15,19]. Operating time and
hospital stay are likely shortened in resections performed
under a low CVP [14]. Therefore, its practice is supported.
However, some controversies regarding the optimum
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anesthetic technique for decreasing CVP have not been
resolved. The stabilization of hemodynamic alterations in
the case of profuse bleeding under a low CVP is the most
difficult part of this method for LR. Intermittent PTC is
developed to minimize the adverse effects of continuous
PTC [6,20]. Intermittent PTC also permits a significant
increase (almost doubling) in ischemia times that can be
achieved with continuous PTC. However, repeated clamp
removal during intermittent PTC may result in fluctuations
of systemic blood pressure, multiple episodes of hepatic IR
injury, and repeated bleeding from transection surfaces. A
systematic metaanalysis has demonstrated that intermittent
PTC reduces blood loss and transfusion requirement
during LR compared with those of the controls. Although
blood loss recorded between the methods of vascular
occlusion does not differ, the application of intermittent
PTC likely shortens the operating time compared with that
of continuous PTC [14].
Numerous devices have been developed to improve
exposure ability and replace clamp crushing [4]. In terms
of blood loss, biliary leak and transection time, several
small randomized trials have not clearly demonstrated
the superiority of any technique [14]. Therefore, the
clamp crushing remains the preferred technique for liver
surgery because of its simplicity and reliability. Bipolar
electrothermal vessel sealers are attractive devices for
the ligation and division of vessels and biliary channels.
Metaanalysis has also suggested the usefulness of this
device in terms of decreasing in blood loss, biliary leak,
and hospital stay compared with that of ligation with
clip and ties [21]. Other advanced techniques for ligation
are radiofrequency (RF)-dissecting sealer and stapler

BODUR et al. / Turk J Med Sci
Table 4. The comparison of variables regarding bleeding amount in operation.
Bleeding amount <500 mL
(n = 189)

Bleeding amount ≥500 mL
(n = 68)

p-value

Age, mean (±SEM)
Sex, n (%)
Male
Female
Liver lesion, n (%)
Benign
Malignant
ASA score, n (%)
ASA 1
ASA 2
ASA 3
ASA 4

55.79 (±13.65)

57.85 (±13.51)

0.284

102 (53.9)
87 (46.1)

47 (69.1)
21 (30.9)

0.032

65 (34.3)
124 (65.7)

18 (26.4)
50 (73.6)

0.290

66 (34.9)
95 (50.2)
27 (14.4)
1 (0.5)

14 (20.5)
46 (67.6)
7 (10.5)
1 (1.4)

BMI, kg/m2, mean (±SEM)

26.53 (±4.27)

26.08 (±4.78)

0.474

DM, n (%)

24 (12.6)

9 (13.2)

1.000

COPD, n (%)

12 (6.3)

2 (2.9)

0.366

CAD, n (%)

12 (6.3)

4 (5.8)

1.000

HBV infection, n (%)

33 (17.4)

15 (22)

0.468

HCV infection, n (%)

16 (8.4)

3 (4.4)

0.418

Presence of cirrhosis
Liver resection, n (%)
Minor
Major
Additional surgery, n (%)

38 (20.1)

19 (27.9)

0.233

142 (75.1)
47 (24.9)
38 (20.1)

26 (38.2)
42 (61.8)
19 (27.9)

<0.001

Operative time, minute, mean (±SEM)

133.07 (±65.41)

218.75 (±105.74)

<0.001

PTC period, minute, mean (±SEM)
Transfusion requirement, n (%)
ES
FFP
Reoperation, n (%)
For bleeding
For other causes

17.11 (±12.12)

29.25 (±13.95)

<0.001

32 (16.9)
128 (67.7)

40 (58.8)
60 (88.2)

<0.001
0.003

1 (0.5)
5 (2.6)

0
2 (2.9)

1.000
1.000

Morbidity, n (%)
Atelectasis
Pleural effusion
Pneumonia
Pulmonary embolism
Pulmonary edema
Surgical site infection
Deep venous thrombosis
Liver failure
Biliary leak
Cardiac complications
Ischemic heart attack
Arrhythmia

53 (28)
40 (21.2)
26 (13.7)
8 (4.2)
3 (1.5)
6 (3.1)
9 (4.7)
1 (0.5)
7 (3.7)
6 (3.1)

29 (42.6)
23 (33.8)
15 (22.1)
7 (10.2)
2 (2.9)
4 (4.8)
6 (8.8)
0
7 (10.2)
11 (16.1)

1 (0.5)
0

1 (1.5)
1 (1.5)

Intensive care unit requirement

17 (8.9)

14 (20.5)

0.080

Postoperative hospital stay, days, median (min–max)

10 (2–97)

13 (3–75)

0.002

30-day mortality, n (%)

5 (2.6)

6 (8.8)

0.041

Follow-up, months, median (min–max)

35 (0–143)

31 (0–129)

0.089

Parameters

0.207

0.233

0.009
0.006
0.124
0.077
0.610
0.463
0.234
1.000
0.058
0.001
0.172
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transection. However, RF-dissecting sealers cause high
infection rates and bleeding complications, while stapler
transection is costly and has a high rate of biliary leaks
[4,22]. Topical hemostatic agents can be classified as
hemostatic matrix agents (collagen, cellulose, gelatin, or
microporous polysaccharide spheres), coagulation factorbased agents (fibrin sealant or topical thrombin), and
combination agents [4]. Various interventions have also
been reported in the literature, but a large heterogeneity
of results indicates weak conclusions on the field [14,23].
Limited evidence has indicated that the application of
combination agents is more efficacious than matrix agents
alone [4].
Despite our intensive efforts devoted to preventing
pulmonary complications, the rate of pulmonary
complications in our practice increased from 20.8% to
27.2% during 6-year period [2]. However, the fatalities of
PE and pneumonia in this period decreased from 100%
to 60% and from 50% to 26.7%, respectively. The overall
biliary leak rate of this study seems comparable with that
of relevant randomized controlled trials in the field. The
overall rate of PHLF seems comparable with that in the
literature. However, our treatment policy was successful
and had a high survival rate after PHLF. Aggressive
attempts to resolving vascular problems related to surgery
and the judicious use of nonbiological liver support in the
treatment algorithm against liver failure are key points to
explain the favorable recovery rates associated with PHLF
[13,24].
The increasing bleeding amount during liver surgery
is strictly correlated with major resection, long operative
time, and prolonged PTC period in this study. The adverse
effects of operative bleeding during liver surgery on
morbidity and mortality were clearly demonstrated. The
small sample size, the absence of randomization, and the

low major LR rate were the main limitations of the study.
In conclusion, different methods are used in
combination to control bleeding during liver surgery.
Each step of bleeding control in this study is based on wellaccepted applications and trusted devices or topical agents.
Morbidity and mortality rates and bleeding amounts are
found within acceptable ranges indicated in the literature.
Although intensive efforts have been devoted to controlling
bleeding, operative bleeding remains a major determinant
of morbidity and mortality in liver surgery. However,
favorable outcomes obtained with diligent postoperative
care can encourage surgeons to achieve better results.
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